Intestinal atresia following chemotherapy, presenting as superior mesenteric artery syndrome: A case report

Multi-agent chemotherapy is recognized as the most common and effective treatment for Burkitt lymphoma, and intestinal mucosal injury is a common gastrointestinal complication following intensive chemotherapy. The aim of the present study was to describe a case of non-Hodgkin lymphoma with intestinal obstruction after chemotherapy in a young adult. The patient presented with aggravated vomiting during the second session of chemotherapy, which was initially attributed to superior mesenteric artery syndrome. However, following surgical intervention, the symptom was proven to be due to extreme intestinal stenosis in the ascending part of the duodenum. The patient underwent duodenojejunectomy and end-to-side anastomosis, and he recovered well from the operation. Although intestinal perforation and hemorrhage induced by chemotherapy have been previously reported sporadically, to the best of our knowledge, this is the first case report of distal duodenal obstruction due to intestinal atresia induced by polychemotherapy for lymphoma. We herein analyze the possible underlying reasons for the intestinal atresia and review the clinical and pathological characteristics of previously published relevant studies. The present findings may be helpful for increasing clinical awareness of this type of complication, as well as improving the management of patients treated with cytotoxic chemotherapeutic agents.

[1]  J. Friedberg,et al.  Treating Burkitt Lymphoma in Adults , 2015, Current Hematologic Malignancy Reports.

[2]  Jiexiong Feng,et al.  Experiences of managing children with acquired intestinal stenosis and atresia , 2015 .

[3]  Tomohiko Nakamura,et al.  Population‐based study of esophageal and small intestinal atresia/stenosis , 2014, Pediatrics international : official journal of the Japan Pediatric Society.

[4]  E. Lin,et al.  Laparoscopic management of duodenal obstruction resulting from superior mesenteric artery syndrome. , 2014, JAMA surgery.

[5]  C. Wiener Harrison's principles of internal medicine , 2013 .

[6]  F. d'Amore,et al.  Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  Sara C. Fallon,et al.  Intestinal perforation after treatment of Burkitt's lymphoma: case report and review of the literature. , 2013, Journal of pediatric surgery.

[8]  J. Coward,et al.  Chemotherapy-induced bowel obstruction in small cell lung cancer: a case report , 2012, Medical Oncology.

[9]  D. Levine,et al.  Incidence of intestinal obstruction following intraperitoneal chemotherapy for ovarian tubal and peritoneal malignancies. , 2009, Gynecologic oncology.

[10]  A. Biankin,et al.  Superior Mesenteric Artery Syndrome: Diagnosis and Treatment Strategies , 2009, Journal of Gastrointestinal Surgery.

[11]  V. Kirimlioğlu,et al.  Spontaneous Intestinal Perforation Due to Non-Hodgkin's Lymphoma: Evaluation of Eight Cases , 2007, Digestive Diseases and Sciences.

[12]  K. Tooley,et al.  A non-invasive method for detection of intestinal mucositis induced by different classes of chemotherapy drugs in the rat , 2006, Cancer biology & therapy.

[13]  R. Hultborn,et al.  Early Disturbance of Microvascular Function Precedes Chemotherapy-Induced Intestinal Injury , 2005, Digestive Diseases and Sciences.

[14]  S. Shankar,et al.  INTESTINAL COMPLICATIONS IN CHILDREN UNDERGOING CHEMOTHERAPY FOR MEDIASTINAL NON-HODGKIN LYMPHOMA , 2004, Pediatric Hematology & Oncology.

[15]  A. King,et al.  Principles of cancer treatment by surgery , 2003 .

[16]  J. Wackenhut,et al.  Burkitt's Lymphoma , 1979, The American journal of nursing.